Multiple SclerosisNCT07847086
Gait Pattern and Its Relation to Cognition and VEP in Multiple Sclerosis
An observational study of Multiple Sclerosis and Gait Disorders, Neurologic, run by Assiut University.
Trial summary
This cross-sectional study aims to assess the pattern of gait in patients with multiple sclerosis and to evaluate its relation to cognitive function, visual evoked potentials, and radiological findings. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Multiple Sclerosis, Gait Disorders, Neurologic
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- 26 Sep 2026to 1 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Study population: Patients with multiple sclerosis attending the Neurology Department outpatient clinic and gait laboratory at Assiut University.
Who may be able to join
- - Age 18 to 55 years
- Confirmed diagnosis of multiple sclerosis according to the revised McDonald criteria
- Clinically stable (no relapse or steroid treatment within 4 weeks)
- Able to walk independently with or without a single assistive device
- Written informed consent
Who cannot join
- - Other neurological, orthopedic, visual, or vestibular conditions affecting gait
- Severe cognitive impairment precluding valid testing
- Pregnancy
- MRI contraindications
- Ocular disease unrelated to multiple sclerosis
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Pattern of Gait and Assessment Regarding Pathophysiology and Mechanism and Its Relation to Cognition, VEP, and Radiology as Prediction of Progression of Disease in Multiple Sclerosis Patients
This cross-sectional study aims to assess the pattern of gait in patients with multiple sclerosis and to evaluate its relation to cognitive function, visual evoked potentials, and radiological findings.
Read the detailed description
Gait impairment is a common and disabling feature of multiple sclerosis. This observational study will include patients with confirmed multiple sclerosis according to the revised McDonald criteria who are clinically stable.
Participants will undergo quantitative gait analysis, cognitive assessment, visual evoked potential testing, and review of MRI findings in a single assessment visit.
- Conditions
- Multiple Sclerosis, Gait Disorders, Neurologic
- Keywords
- Visual evoked potentials, Multiple sclerosis, Gait analysis, Cognition, Assiut
- Medical subject headings
- Multiple Sclerosis, Gait Disorders, Neurologic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Single cohort: Multiple Sclerosis Patients | Patients with confirmed multiple sclerosis who will undergo gait analysis, cognitive testing, visual evoked potential assessment, and MRI review in a single visit. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean gait velocity
Mean gait velocity in meters per second measured by quantitative spatiotemporal gait analysis.
Measured: Baseline
Secondary outcomes (5)
Mean cadence
Mean cadence in steps per minute measured by quantitative gait analysis.
Measured: Baseline
Mean stride length
Mean stride length in centimeters measured by quantitative gait analysis.
Measured: Baseline
Mean MoCA score
Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition).
Measured: Baseline
Mean P100 latency
Mean P100 latency in milliseconds measured by pattern-reversal visual evoked potentials.
Measured: Baseline
Mean EDSS score
Mean Expanded Disability Status Scale (EDSS) score (range 0-10, higher scores indicate worse disability).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2026
- Study start26 Sep 2026 (estimated)
- Primary completion26 Sep 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Manar Moataz Abdel-ghani, Assiut University
- Investigators
- Tarek A Rageh, prof, Study chair, Neuropsychiatry Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07847086
- Sponsor's protocol ID
- MS-Gait-Assiut-2026
- Status last verified
- Sep 2026
- First submitted
- 23 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pattern of Gait and Assessment Regarding Pathophysiology and Mechanism and Its Relation to Cognition, VEP, and Radiology as Prediction of Progression of Disease in Multiple Sclerosis Patients
- ClinicalTrials.gov ID
- NCT07847086
- Acronym / sponsor ID
- MS-Gait-Assiut-2026
- Conditions
- Multiple Sclerosis, Gait Disorders, Neurologic
- Keywords
- Visual evoked potentials, Multiple sclerosis, Gait analysis, Cognition, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 26 Sep 2026 (estimated)
- Primary completion
- 26 Sep 2027 (estimated)
- Study completion
- 1 Mar 2028 (estimated)
- First posted
- 29 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to assess the pattern of gait in patients with multiple sclerosis and to evaluate its relation to cognitive function, visual evoked potentials, and radiological findings.
Detailed description
Gait impairment is a common and disabling feature of multiple sclerosis. This observational study will include patients with confirmed multiple sclerosis according to the revised McDonald criteria who are clinically stable.
Participants will undergo quantitative gait analysis, cognitive assessment, visual evoked potential testing, and review of MRI findings in a single assessment visit.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single cohort: Multiple Sclerosis Patients | – | –Patients with confirmed multiple sclerosis who will undergo gait analysis, cognitive testing, visual evoked potential assessment, and MRI review in a single visit. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients with multiple sclerosis attending the Neurology Department outpatient clinic and gait laboratory at Assiut University.
Key inclusion criteria (5 listed)
- - Age 18 to 55 years
- Confirmed diagnosis of multiple sclerosis according to the revised McDonald criteria
- Clinically stable (no relapse or steroid treatment within 4 weeks)
- Able to walk independently with or without a single assistive device
- Written informed consent
Key exclusion criteria (5 listed)
- - Other neurological, orthopedic, visual, or vestibular conditions affecting gait
- Severe cognitive impairment precluding valid testing
- Pregnancy
- MRI contraindications
- Ocular disease unrelated to multiple sclerosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mean gait velocity
Time frame: Baseline
Mean gait velocity in meters per second measured by quantitative spatiotemporal gait analysis.
5 secondary outcomes
Mean cadence
Time frame: Baseline
Mean stride length
Time frame: Baseline
Mean MoCA score
Time frame: Baseline
Mean P100 latency
Time frame: Baseline
Mean EDSS score
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tarek A Rageh, prof study chair
Neuropsychiatry Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis and Gait Disorders, Neurologic, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Manar A Ali, Resident (01091423914, manarmoataz2000@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean gait velocity (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.